Blocktran, 50 mg, film-coated tablets, 60 pcs.
Hypersensitivity reactions
In patients with a history of angioedema (swelling of the face, lips, pharynx/larynx and/or tongue), monitoring of the use of the drug is necessary (see “Side effects”).
Embryotoxicity
The use of drugs that affect the RAAS during the second and third trimester of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and mortality. The development of oligohydramnios may be associated with fetal lung hypoplasia and skeletal deformities. Possible adverse events in neonates include calvarial hypoplasia, anuria, hypotension, renal failure and death. When diagnosing pregnancy, the drug Blocktran® should be taken immediately.
Arterial hypotension and water-electrolyte imbalance or decreased circulating blood volume
In patients with reduced blood volume (for example, those receiving treatment with large doses of diuretics), symptomatic arterial hypotension may occur. Correction of such conditions must be carried out before prescribing Bloktran® or starting treatment with a lower dose of Bloktran® (see “Dosage and Administration”). Fluid and electrolyte imbalance is common in patients with impaired renal function with or without diabetes mellitus, so careful monitoring of these patients is necessary.
Losartan in patients with type 2 diabetes mellitus with proteinuria increases the incidence of hyperkalemia.
During treatment with Bloktran®, it is not recommended to take potassium-sparing diuretics, potassium supplements or potassium-containing salt substitutes.
Aortic or mitral stenosis, hypertrophic obstructive cardiomyopathy
Like all drugs that have a vasodilating effect, ARA II should be prescribed with caution to patients with aortic or mitral stenosis or hypertrophic obstructive cardiomyopathy.
Coronary heart disease and cerebrovascular diseases
Like all drugs that have a vasodilating effect, ARA II should be prescribed with caution to patients with coronary heart disease or cerebrovascular diseases, since an excessive decrease in blood pressure in this group of patients can lead to the development of myocardial infarction or stroke.
Chronic heart failure
As with the use of other drugs that act on the RAAS, in patients with CHF and with or without impaired renal function, there is a risk of developing severe hypotension or acute renal impairment.
Since there is insufficient experience with the use of losartan in patients with heart failure and concomitant severe renal impairment, in patients with severe heart failure (NYHA functional class IV), as well as in patients with heart failure and symptomatic life-threatening arrhythmias, the drug Blocktran® should be prescribed with caution to patients in these groups.
Primary hyperaldosteronism
Since patients with primary hyperaldosteronism, as a rule, do not have a positive response to therapy with antihypertensive drugs that act by inhibiting the RAAS, the use of Bloktran® is not recommended in this group of patients.
Liver dysfunction
Data from pharmacokinetic studies indicate that the concentration of losartan in the blood plasma in patients with cirrhosis of the liver increases significantly, therefore patients with a history of impaired liver function should be prescribed Bloktran® at a lower dose. There is no experience with the use of losartan in patients with severe liver dysfunction, so the drug should not be used in this group of patients (see “Pharmacological properties” (Pharmacokinetics); “Contraindications”; “Dosage and administration”).
Renal dysfunction
Due to inhibition of the RAAS, changes in renal function, including the development of renal failure, have been observed in some susceptible patients. These changes in renal function may return to normal after treatment is stopped.
Some drugs that affect the RAAS may increase blood urea and serum creatinine concentrations in patients with bilateral renal artery stenosis or renal artery stenosis of a solitary kidney. Similar effects have been reported with losartan. Such renal dysfunction may be reversible after discontinuation of therapy. Losartan should be used with caution in patients with bilateral renal artery stenosis or renal artery stenosis of a solitary kidney.
Concomitant use of angiotensin II receptor antagonists with drugs containing aliskiren is contraindicated in patients with diabetes mellitus and/or with moderate or severe renal impairment (GFR less than 60 ml/min/1.73 m2 body surface area) and is not recommended in other patients ( see section "Contraindications").
Concomitant use of angiotensin II receptor antagonists with ACE inhibitors is contraindicated in patients with diabetic nephropathy and is not recommended in other patients (see section "Contraindications").
Special patient groups
Race
Losartan, compared with atenolol, reduces cardiovascular morbidity and mortality in patients with hypertension and left ventricular hypertrophy of all races except blacks.
Children and teenagers
The effectiveness and safety of losartan in children and adolescents under 18 years of age have not been established.
If oliguria or arterial hypotension develops in newborns whose mothers took losartan during pregnancy, symptomatic therapy aimed at maintaining blood pressure and renal perfusion is necessary. Blood transfusions or dialysis may be required to prevent hypotension and/or maintain renal function.
Elderly patients
Clinical studies have not revealed any particularities regarding the safety and effectiveness of losartan in elderly patients (over 65 years of age).
Impact on the ability to drive vehicles and machinery
During the treatment period, caution should be exercised when driving and engaging in other potentially hazardous activities, since some of the side effects observed with the use of losartan, such as dizziness, drowsiness, may adversely affect the ability to drive a vehicle and perform potentially hazardous activities requiring increased concentration of attention and speed of psychomotor reactions.
Brief information about the drug
The drug for high blood pressure Bloktran belongs to the pharmacological group of angiotensin 2 receptor antagonist drugs. It is produced in Russia.
Release form
The blood pressure medicine Blocktran is presented on the pharmaceutical market in a convenient tablet form. The manufacturer produces tablets packaged in blisters of 10 pieces. You can purchase either 1 blister or a box containing 2, 3, 5 or 6 blisters.
Packaging of Blocktran tablets
Composition of tablets
The main active component of the drug is potassium losartan, presented in a dose of 12.5 mg or 50 mg.
The composition of the tablets also includes additional ingredients: starch, sodium carboxymethyl starch, magnesium stearate, lactose monohydrate, povidone, silicon dioxide, microcrystalline cellulose.
Terms and conditions of storage
The tablets should be stored in a place inaccessible to children and pets, protected from moisture and direct sunlight. The recommended storage temperature should not exceed +30°C.
The maximum shelf life of the drug is 2 years.
Terms of sale
It is possible to purchase medication in pharmacy chains only after presenting an appropriate medical prescription.
Price
The cost of the drug is influenced by factors such as the dosage of the main active ingredient and the number of tablets in the package. The approximate price for Blocktran varies from 150 rubles to 400 rubles.
Pharmacological characteristics
The drug Bloktran has a pronounced antihypertensive pharmacological effect.
Is it possible to drive a car?
Possible side effects of Bloktran include dizziness, increased drowsiness, and asthenia. For this reason, in the first days of the therapeutic course you should refrain from driving. In the future (if the condition is normal and there are no undesirable reactions from the central nervous system), the patient can get behind the wheel, using extreme caution.
Driving a car while taking Blocktran is possible in the absence of adverse reactions to the drug
Manifestations of side effects
Treatment with Blocktran tablets can cause the following adverse reactions:
- Arterial hypotension (excessive decrease in blood pressure);
- Pulse abnormalities (tachycardia or bradycardia);
- Decreased sexual desire;
- Erectile dysfunction in male patients;
- Rhinitis;
- Convulsive syndrome;
- Increased urge to empty the bladder;
- Cough syndrome;
- Conjunctivitis;
- Noise and ringing in the ears;
- Deterioration of visual function;
- Diarrhea or constipation;
- Dyspeptic disorders;
- Bronchitis;
- Dizziness;
- Migraine attacks;
- Depressive states;
- Nausea and vomiting;
- Toothache;
- Permanent lack of appetite, up to anorexia;
- Painful sensations localized in the sternum, lower extremities, back, knee joint, shoulder region;
- Skin itching;
- Rash on the skin like urticaria;
- Anemia;
- Tremor;
- Problems with sleep (insomnia or increased sleepiness);
- Chronic fatigue syndrome, weakness, asthenia, decreased performance;
- Hair loss;
- Increased sweating;
- Excessive dryness of the skin;
- Memory impairment;
- Psycho-emotional instability, causeless nervousness, anxiety, restlessness.
In most cases, the drug is well tolerated, and possible side effects disappear on their own after a few days of treatment. If the condition worsens, you should definitely inform your doctor about it!
Lack of appetite may be a side effect of taking the pills
Drug interactions
Combination with potassium-containing drugs and diuretics increases the likelihood of developing hyperkalemia.
Tablets can be combined with other antihypertensive medications, diuretics, beta-blockers, but in smaller doses, due to an increased hypotensive effect.
You should ask your doctor about compatibility with other drugs.
When use is contraindicated
Medical specialists categorically prohibit drinking Blocktran for high blood pressure in patients who have the following clinical contraindications:
- Dehydration;
- Hypotonic disease (stably reduced blood pressure);
- Hyperkalemia;
- Individual intolerance and hypersensitivity to substances included in the tablets.
With particular caution, the drug is prescribed to persons with diagnosed liver failure or renal dysfunction. Treatment of this category of patients requires strict medical supervision, individual dosing and constant monitoring of health status.
Pharmacokinetics of the drug
Blocktran reduces blood pressure 6 hours after taking the tablets. The therapeutic effect lasts throughout the day, avoiding the need for frequent medication use. The maximum concentration of the active substances of the drug in the blood is observed after 3-4 hours.
The medicine is eliminated from the body within 9 hours, through the gastrointestinal tract (60%), another 35% of the medicine is excreted through the renal apparatus, along with urine.
Pharmacodynamics - increases or decreases blood pressure
Blood pressure tablets Blocktran suppress specific angiotensin receptors localized in the area of blood vessels, adrenal glands, heart and kidney apparatus.
Blocktran lowers blood pressure. Since the drug has a cumulative effect, the hypotensive effect becomes most noticeable after a month of the therapeutic course.
Bloktran is effective when used as a course
Increases renin levels in the blood without negatively affecting the production and functioning of other hormones responsible for the normal functioning of the cardiovascular system, which avoids a number of side effects characteristic of most antihypertensive drugs.
Helps increase life expectancy in patients suffering from cardiac ventricular hypertrophy and hypertension.
Important Notes
During the therapeutic course, it is necessary to regularly monitor potassium levels in the blood, especially if we are talking about elderly people or patients with diagnosed renal dysfunction.
Before starting treatment, it is recommended to correct dehydration. If this cannot be done for certain reasons, then therapy begins with minimal dosages of the drug.
In patients suffering from dehydration, tablets can provoke the development of a hypotensive crisis.
